Turkel Susan Beckwitt, Jacobson Julienne, Munzig Elizabeth, Tavaré C Jane
Department of Psychiatry, University of Southern California Keck School of Medicine, Children's Hospital Los Angeles, Los Angeles, California 90027, USA.
J Child Adolesc Psychopharmacol. 2012 Apr;22(2):126-30. doi: 10.1089/cap.2011.0084. Epub 2012 Feb 24.
Atypical antipsychotics have been documented to be effective in the management of delirium in adults, but despite considerable need, their use has been less studied in pediatric patients.
A retrospective chart review was done to describe the use of atypical antipsychotics in controlling symptoms of delirium in children and adolescents.
Pharmacy records at Children's Hospital Los Angeles were reviewed to identify patients to whom antipsychotic agents were dispensed over a 24-month period. Psychiatric inpatient consultations during the same 24-month period were reviewed. Patients 1-18 years old diagnosed with delirium given antipsychotics constituted the study population. Delirium Rating Scale-Revised-98 (DRS-R98) scores were retrospectively calculated, when possible, at time antipsychotic was started to confirm the initial diagnosis of delirium and evaluate symptom severity, and again when antipsychotic was stopped, to assess symptom response.
Olanzapine (n=78), risperidone (n=13), and quetiapine (n=19) were used during the 2 years of the study. Mean patient age, length of treatment, and response were comparable for the three medications. For patients with two DRS-R98 scores available (n=75/110), mean DRS-R98 scores decreased significantly (p<0.001) with antipsychotic without significant adverse side effects.
Although randomized placebo-controlled studies are needed, atypical antipsychotic medications appeared to be effective and safe for managing delirium symptoms in pediatric patients while underlying etiology was addressed.
已有文献证明非典型抗精神病药物在成人谵妄管理中有效,但尽管有很大需求,其在儿科患者中的使用研究较少。
进行一项回顾性病历审查,以描述非典型抗精神病药物在控制儿童和青少年谵妄症状中的使用情况。
回顾了洛杉矶儿童医院的药房记录,以确定在24个月期间接受抗精神病药物治疗的患者。同时回顾了同一24个月期间的精神科住院会诊记录。年龄在1至18岁、被诊断为谵妄并接受抗精神病药物治疗的患者构成研究人群。在开始使用抗精神病药物时,尽可能回顾性计算谵妄评定量表修订版98(DRS-R98)得分,以确认谵妄的初始诊断并评估症状严重程度;在停用抗精神病药物时再次计算得分,以评估症状反应。
在研究的两年中,使用了奥氮平(n = 78)、利培酮(n = 13)和喹硫平(n = 19)。三种药物的平均患者年龄、治疗时长和反应相当。对于有两个DRS-R98得分的患者(n = 75/110),使用抗精神病药物后,DRS-R98平均得分显著降低(p < 0.001),且无明显不良副作用。
尽管需要进行随机安慰剂对照研究,但在处理潜在病因的同时,非典型抗精神病药物似乎对管理儿科患者的谵妄症状有效且安全。